Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2022-11-01 M&A Activity
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service in South Korea. It details the finalization of an asset acquisition (자산양수도) involving the transfer of convertible bonds. Since this document reports on the completion of a specific corporate transaction (M&A/Asset acquisition), it falls under the M&A Activity category.
2022-11-01 Korean
주요사항보고서(주권관련사채권양수결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange. It details the acquisition of convertible bonds (주권 관련 사채권 양수 결정), including specific terms, counterparty information, and financial data. This type of regulatory filing in the Korean market is a standard disclosure for material corporate events, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (TAR) or Share Issue (SHA) exclusively, but rather serves as a general mandatory disclosure.
2022-10-26 Korean
주권관련사채권의취득결정(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '주권 관련 사채권의 취득결정' (Decision to acquire equity-related bonds), which is a standard disclosure format in the Korean market (DART system). It details the acquisition of convertible bonds, including terms, issuer information, financial summaries, and call option details. This falls under the category of capital and financing updates as it relates to the company's investment and debt structure.
2022-10-25 Korean
전환가액의조정(제5회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from a Korean company (AdBiotech) regarding the adjustment of the conversion price of convertible bonds (CB). This type of disclosure, which details changes to capital structure instruments like convertible debt, falls under the category of capital and financing updates.
2022-09-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is a '정정신고' (Amendment Report). It details changes to stock option grants, including the number of shares and the list of recipients. In the context of financial filings, reports regarding the issuance or modification of stock options (which affect capital structure and equity) are classified under 'Share Issue/Capital Change' (SHA) as they represent changes to the company's potential share capital and equity-based compensation structure.
2022-09-02 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'AdBiotech' covering the period from January 1, 2022, to June 30, 2022. It contains detailed company information, business descriptions, financial data, and management reports. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) that contains substantive financial data is classified as an Interim / Quarterly Report (IR). H1 2022
2022-08-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.